HYDIN and melanoma: As shown in Figure 2B, there was no remarkable difference in OS between HYDIN-MUT patients and HYDIN-WT patients (HR = 0.819 [95% CI, 0.616–1.088], Plog rank = 0.167), which confirmed that HYDIN mutations can be used as potential predictive biomarkers for anti-PD-1 treatment of melanoma patients.